1. Generics Bulletin
  2. >>Business

Stada Grows In Russia And CIS With Takeda Deal

Stada To Pay $660m For 20 OTC And Prescription Brands

 
• By Tom Gallen

Stada will pay $660m for a basket of 20 brands from Takeda to expand its consumer health portfolio in Russia and a number of strategically important CIS markets.

Russia
Stada Will Grow In Russia And The CIS Via The Takeda Deal • Source: Shutterstock

Stada Arzneimittel AG is beefing up its presence in Russia and the Commonwealth of Independent States (CIS) by snapping up a portfolio of OTC and prescription brands from Japan’s Takeda Pharmaceutical Co. Ltd. for $660m.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

Roche Suggests Perjeta Biosimilars May Not Hit Until 2027 ‘Or Later’

 
• By Dean Rudge

Amid several insights into its expectations of biosimilar competition in 2025, Roche has confirmed the total amount it anticipates being shaved from its top line this year.

Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition

 
• By Adam Zamecnik

Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.